We are delighted to inform you that Panacea Biotec Ltd. has received a Letter of Award dated 10.04.2026 from Central Medical Services Society, Ministry of Health and Family Welfare, Government ....
ORDERS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 11 Apr 2026, 04:01 PM IST · BSE ID: 19bcc6bd-94e4-4c9f-b1ff-2ea171a0acfb
View Original BSE Filing (PDF)
⚡ Quick Answer
Panacea Biotec Ltd. has been awarded a contract valued at INR 20.79 Crore from the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India. This award is for the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP. Deliveries are scheduled from September/October 2026 to November/December 2028.
💡
In Simple Terms
The company won a government contract worth INR 20.79 Crore to supply adult tetanus and diphtheria vaccines over two years starting late 2026.
🤖 AI Summary
- Panacea Biotec awarded Letter of Award by CMSS for Td Vaccine supply worth INR 20.79 Crore
- Supply contract spans September/October 2026 to November/December 2028 in multiple tranches
- Order from Central Medical Services Society, Ministry of Health and Family Welfare, Government of India
- Domestic government order with no promoter group interest or related party transactions
🔢 Key Numbers — exact figures from BSE filing, not rounded
Contract value
INR 20.79 Crore
Execution period
September/October 2026 to November/December 2028
Product
Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP
Awarding entity
Central Medical Services Society, Ministry of Health and Family Welfare, Government of India
🏢 How This Affects the Company
Adds INR 20.79 Crore vaccine supply contract to revenue pipeline. Extends company's domestic government healthcare supply relationships through December 2028.
Contract value of INR 20.79 Crore will be recognized over execution period September 2026 to December 2028. Revenue timing and cash flow depend on CMSS payment terms and tranche delivery schedules.
Company must scale vaccine manufacturing and supply chain to deliver multiple tranches to CMSS from September 2026 onwards. Requires sustained production capacity and logistics coordination over 28-month period.
Government order dependent on CMSS payment discipline and demand schedule. Potential risks from regulatory changes to vaccine specifications, supply chain disruptions, or government policy shifts.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required. Monitor Q4 FY26 and Q1 FY27 management commentary for supply chain readiness and payment term confirmation.
👤
Who Is Affected
All shareholders benefit from revenue visibility and government order validation. No segment restrictions. Cash flow timing affects working capital efficiency for all equity holders.
🔍
Management Signal
Management has secured domestic government vaccine supply mandate, signaling successful regulatory compliance, product quality, and institutional sales capability in healthcare procurement.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q4 FY26 and Q1 FY27 earnings calls — confirmation of vaccine supply chain readiness for September 2026 ramp-up.
H1 FY27 results filing — track revenue recognition from first tranches and actual CMSS payment receipt timing.
Management commentary on government repeat orders — validation of order win as foundation for larger domestic healthcare contracts.
MEDIUM RISK
Government payment delays, tranche delays, regulatory changes, or supply chain disruptions could affect revenue timing and cash flow. Execution over 28 months carries operational risk.
💡 Investor Takeaway
Panacea Biotec secured INR 20.79 Crore government contract to supply adult tetanus-diphtheria vaccine from September 2026 through December 2028. This validates domestic market access but lacks disclosed payment terms and quarterly milestone detail essential for revenue timing assessment.
⚖️ Strengths & Concerns
✅ Positives
- Direct government order from Ministry of Health validates product regulatory compliance and quality standards domestically.
- INR 20.79 Crore contract spanning 28 months provides multi-year revenue visibility and cash flow predictability for vaccine segment.
⚠️ Concerns
- No disclosed payment terms, milestones, or penalties in filing — financial risk profile and cash timing unclear to investors.
- Delivery timeline spans two years with undefined quarterly tranches — lumpy revenue recognition and execution risk not quantified.
❓ Frequently Asked Questions
What is the value of the Letter of Award received by Panacea Biotec Ltd.?
Panacea Biotec Ltd. has received a Letter of Award with an aggregate value of INR 20.79 Crore.
Who awarded the contract to Panacea Biotec Ltd.?
The contract was awarded by the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, Government of India.
What product will Panacea Biotec Ltd. supply under this award?
Panacea Biotec Ltd. will supply Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP (Td Vaccine).
What is the execution period for the Td Vaccine supply contract?
The execution period for the Td Vaccine supply contract is from September/October 2026 through November/December 2028.
Is the contract awarded to Panacea Biotec Ltd. a related party transaction?
No, the transaction is not a related party transaction, and there is no promoter group interest in the awarding entity, CMSS.
Questions based on this BSE filing only. For information purposes.